A5090173867- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Heart Failure Treatment and Management
- Immunotherapy and Immune Responses
- Cancer Genomics and Diagnostics
- Lung Cancer Diagnosis and Treatment
- Cardiac Arrhythmias and Treatments
- Ferroptosis and cancer prognosis
- Cardiac electrophysiology and arrhythmias
- Potassium and Related Disorders
- Brain Metastases and Treatment
- Colorectal Cancer Treatments and Studies
- Atrial Fibrillation Management and Outcomes
- Lung Cancer Research Studies
University Hospital Heidelberg
2023-2025
Heidelberg University
2016-2025
National Center for Tumor Diseases
2024-2025
German Center for Lung Research
2023-2024
Abstract Background Predictive biomarkers in use for immunotherapy advanced non-small cell lung cancer are of limited sensitivity and specificity. We analysed the potential activating KRAS pathogenic TP53 mutations to provide additional predictive information. Methods The study cohort included 713 consecutive patients with adenocarcinomas, negative actionable genetic alterations. Additionally, two previously published surgical patient cohorts were analyzed. Therapy benefit was stratified by...
Abstract Oligometastatic (OMD) non‐small cell lung cancer (NSCLC) is a distinct but heterogeneous entity. Current guidelines recommend systemic therapy and consolidation with local ablative (LAT). However, evidence regarding the optimal choice of multimodal treatment approaches lacking, in particular respect to integration immunotherapy. This real‐world study identified 218 patients OMD NSCLC (2004–2023, prespecified criteria: ≤5 metastases ≤2 organ systems) from three major German...
Abstract This study analyzed whether extended molecular profiling can predict the development of epidermal growth factor receptor ( EGFR ) gene T790M mutation, which is most frequent resistance alteration in non‐small cell lung cancer (NSCLC) after treatment with first‐/second‐generation (1G/2G) inhibitors (tyrosine kinase [TKIs]), but only weakly associated clinical characteristics. Whole exome sequencing (WES) was performed on pretreatment tumor tissue matched normal samples from NSCLC...
Background Immunotherapies targeting the programmed death receptor-1/programmed ligand-1(PD-1/PD-L1) checkpoint have a major impact on treatment of both resectable and advanced non-small cell lung cancer (NSCLC). Additional blockade T-cell immunoreceptor with immunoglobulin tyrosine-based inhibition motif domain (TIGIT)-receptor may synergistically foster immune-related response. Several trials are currently investigating combination neoadjuvant platinum-based chemotherapy dual prior to...
Abstract PD-L1 protein expression is the most important predictive biomarker for immune checkpoint inhibition (ICI) in advanced non-small cell lung cancer (NSCLC), but has limited sensitivity and specificity. We analyzed potential of activating KRAS pathogenic TP53 mutations to provide additional information. The study cohort included 713 consecutive immunotherapy patients with adenocarcinomas Thoraxklinik Heidelberg who were negative actionable EGFR ALK/RET/ROS1 alterations. Two external...
Brain metastases (BMs) are a key challenge in the management of anaplastic lymphoma kinase-rearranged non-small-cell lung cancer (ALK+ NSCLC), but prognostic scores complicated or rely on data before era tyrosine kinase inhibitors (TKIs). This study aimed to validate novel ALK-Brain Prognostic Index (ALK-BPI), which was originally proposed based 44 TKI-treated ALK+ NSCLC patients from Karolinska University Hospital, using an external clinical cohort.
Abstract Aims Co‐morbid atrial fibrillation (AF) increases both mortality and N‐terminal pro brain natriuretic peptide (NT‐proBNP) concentrations in patients with chronic heart failure (CHF). It is unclear whether AF worsens prognosis independently from NT‐proBNP concentrations. If was an independent risk factor, levels for outcome prediction would need to be adjusted AF. We aimed analyse the influence of on prognostic value CHF. Methods results A total 2541 consecutive CHF sinus rhythm (SR)...